Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + bevacizumab + albumin-bound paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy is an investigational first-line regimen for locally advanced or metastatic cholangiocarcinoma, integrating immunotherapy, anti-angiogenic therapy, and cytotoxic chemotherapy. Sintilimab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby restoring T-cell antitumor activity. Bevacizumab is a monoclonal antibody that targets VEGF-A, inhibiting angiogenesis and potentially normalizing tumor vasculature to improve drug delivery and immune cell infiltration. The AG regimen consists of albumin-bound paclitaxel (nab-paclitaxel), a microtubule stabilizer, and gemcitabine, a nucleoside analog that inhibits DNA synthesis. This multi-pronged approach aims to enhance the objective response rate and survival outcomes in patients with biliary tract cancers.
- Brand names
- Abraxane
- Other names
- Sintilimab plus bevacizumab and AG regimenSintilimab + bevacizumab + nab-paclitaxel + gemcitabine
02
Targets
DNADNA polymerase familyPDCD1 (Programmed cell death protein 1 receptor)gp60 (GP60 Receptor)TUBB (Tubulin (alpha and beta subunits))SPARC (Secreted protein acidic and rich in cysteine)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on sintilimab + bevacizumab + albumin-bound paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + bevacizumab + albumin-bound paclitaxel + gemcitabine.